Clinical effect of etoposide combined with nedaplatin in the treatment of patients with advanced ovarian cancer and its effect on prognosis and QOL score
Objective:To explore the clinical effect of etoposide combined with nedaplatin in the treatment of patients with ad-vanced ovarian cancer and its effect on prognosis and QOL score.Methods:66 patients with advanced ovarian cancer from June 2022 to May 2023 in our hospital were randomly divided into two groups,33 cases in each group.The control group received et-oposide combined with cisplatin,the study group received etoposide combined with nedaplatin.The short-term efficacy,adverse reactions,quality of life(QOL)score and prognosis were compared between the two groups.Results:Compared with the control group,the total effective rate,psychological status,body function and self-care QOL score and survival rate were higher in the study group(P＜0.05),there was no significant difference in the incidence of nausea and vomiting in the study group(P＞0.05),and the incidence of adverse reactions such as neurotoxicity,hair loss,and the recurrence rate and mortality rate were lower(P＜0.05).Conclusion:The application of etoposide combined with nedaplatin chemotherapy in patients with advanced o-varian cancer can effectively reduce the incidence of adverse reactions,ensure the safety of patients during treatment,improve the prognosis of patients and improve their quality of life,has a significant short-term efficacy.
万方数据
维普
